Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9462503 | 1.00 | FDPS (0.51) | FDPSTSHRGRIA1GRIA2GRIA4 | |
| SCHEMBL503649 | 1.00 | FDPS (0.51) | FDPSTSHRGRIA1GRIA2GRIA4 | |
| Hydrochloric Acid SCHEMBL7471557 | 0.98 | FDPS (0.50) | FDPSTSHRGRIA1GRIA2GRIA4 | |
| SCHEMBL10222182 | 0.84 | FDPS (0.50) | FDPSTSHRHDAC1HDAC6HTT | |
| SCHEMBL5322003 | 0.82 | ARG1 (0.44) | FDPSTSHRGRIA1GRIA2GRIA4 | |
| SCHEMBL15208660 | 0.82 | ARG1 (0.44) | FDPSTSHRGRIA1GRIA2GRIA4 | |
| SCHEMBL10206691 | 0.81 | FDPS (0.47) | FDPSTSHRHDAC1HDAC6HTT | |
| SCHEMBL15209057 | 0.80 | ARG1 (0.52) | FDPSTSHRALDH1A1TDP1CYP1A2 | |
| SCHEMBL15209056 | 0.80 | ARG1 (0.52) | FDPSTSHRALDH1A1TDP1CYP1A2 | |
| SCHEMBL8781449 | 0.80 | FDPS (0.46) | FDPSTSHRHDAC1HDAC6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115015460-B | Method for identifying cordyceps sinensis producing area by using wide-range targeted metabonomics technology | 中国检验检疫科学研究院 | 2024-05-03 | — | — | CN | claimed |
| CN-115015460-A | Method for identifying producing area of cordyceps sinensis by using extensive targeted metabonomics technology | 中国检验检疫科学研究院 | 2022-09-06 | — | — | CN | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-115015460-B | Method for identifying cordyceps sinensis producing area by using wide-range targeted metabonomics technology | 中国检验检疫科学研究院 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-115093463-A | Beta-hairpin peptidomimetics | 波利弗尔股份公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115015460-A | Method for identifying producing area of cordyceps sinensis by using extensive targeted metabonomics technology | 中国检验检疫科学研究院 | 2022-09-06 | — | — | CN | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
| US-4328134-A | Anorexigenic peptides | ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND, THE, A CORP. OF LA | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | FDPS 1109/4885TSHR 1147/4885GRIA1 1041/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | FDPS 2740/4885TSHR 182/4885GRIA1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.